The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia

International Journal of COPD

Volumn 10, Issue 1, 2015, Pages 2469-2478

  Duman, Dildar ^a   Aksoy, Emine ^a   Agca, Meltem Coban ^a   Kocak, Nagihan Durmus ^a   Ozmen, Ipek ^a   Akturk, Ulku Aka ^a   Gungor, Sinem ^a   Tepetam, Fatma Merve ^a   Eroglu, Selma Aydogan ^a   Oztas, Selahattin ^a   Karakurt, Zuhal ^a  

^a Sureyyapasa Chest Diseases and Thoracic Surgery Teaching Hospital   (Turkey)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation; Mortality; Peripheral eosinophilia

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; GLUCOSE; AUTACOID;

ADULT; AGED; ARTICLE; BASOPHIL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MORTALITY; NEUTROPHIL LYMPHOCYTE RATIO; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; SURVIVAL TIME; THROMBOCYTE VOLUME; UREA NITROGEN BLOOD LEVEL; BLOOD; CHI SQUARE DISTRIBUTION; DISEASE COURSE; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOCYTE; MIDDLE AGED; NEUTROPHIL; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EOSINOPHILIA; RISK ASSESSMENT; RISK FACTOR; TEACHING HOSPITAL; TERTIARY CARE CENTER; THROMBOCYTE; THROMBOCYTE COUNT; TIME FACTOR; TURKEY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; BLOOD PLATELETS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; HOSPITALS, TEACHING; HUMANS; INFLAMMATION MEDIATORS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MEAN PLATELET VOLUME; MIDDLE AGED; NEUTROPHILS; PATIENT READMISSION; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EOSINOPHILIA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TERTIARY CARE CENTERS; TIME FACTORS; TURKEY;

EID: 84947104812     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S90330     Document Type: Article

References (36)

1. Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]. Global strategy for diagnosis, management, and prevention of COPD [updated 2012]. Available from: http://www.goldcopd.org. Accessed October 5, 2015.
2. Singanayam A, Schembri S, Chalmers JD. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. A systematic review and meta-analysis. Ann Am Thorac Soc. 2013;10(2):81–89.
3. Brightling CE. Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10 Suppl:S214–S219.
4. Tertemiz KC, Kömüs N, Ellidokuz H, Sevinç C, Cımrın AH. Kronik obstrüktif akciğer hastalığında mortalite ve mortaliteyi etkileyen faktörler [Mortality and factors affecting mortality in chronic obstructive pulmonary disease]. Tuberk Toraks. 2012;60(2):114–122. Turkish.
5. Gunen H, Hacievliyagil SS, Kosar F, et al. Factors affecting survival of hospitalized patients with COPD. Eur Respir J. 2005;26(2):234–241.
6. Gunay E, Sarınç Ulaşlı S, et al. Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. Inflam­mation. 2014;37(2):374–830.
7. Siva R, Gren RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29(5):906–913.
8. Bafadhel M, Davies L, Calverley PM, Aaron SD, Brightling CE, Pavord ID. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J. 2014;44(3): 789–791.
9. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clus­ters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671.
10. Bafadhel M, McCormick M, Saha S, et al. Profiling of sputum inflam­matory mediators in asthma and chronic obstructive pulmonary disease. Respiration. 2012;83(1):36–44.
11. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmo­nary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48–55.
12. Iliaz S, Iliaz R, Ortakoylu G, Bahadir A, Bagci BA, Caglar E. Value of neutrophil/lymphocyte ratio in the differential diagnosis of sarcoidosis and tuberculosis. Ann Thorac Med. 2014;9(4):232–235.
13. Ulasli SS, Ozyurek BA, Yilmaz EB, Ulubay G. Mean platelet volume as an inflammatory marker in acute exacerbation of chronic obstructive pulmonary disease. Pol Arch Med Wewn. 2012;122(6):284–290.
14. Wang RT, Li JY, Cao ZG, Li Y. Mean platelet volume is decreased during an acute exacerbation of chronic obstructive pulmonary disease. Respirology. 2013;18(8):1244–1248.
15. Cedrés S, Torrejon D, Martínez A, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012;14(11):864–869.
16. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91(3):181–184.
17. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008;102(6):653–657.
18. Sahin F, Yazar E, Yıldız P. Prominent features of platelet count, platelet­crit, mean platelet volume and platelet distribution width in pulmonary tuberculosis. Multidiscip Respir Med. 2012;7(1):38.
19. Kisacik B, Tufan A, Kalyoncu U, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008;75(3):291–294.
20. Liu S, Jianan R, Han G, et al. Mean platelet volume: a controver­sial marker of disease activity in Crohn’s disease. Eur J Med Res. 2012;17:27.
21. Anthonisen NR, Manfreda J, Warren CP, Hersfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Inter Med. 1987;106(6):196–204.
22. Mirsaeidi M, Peyrani P, Aliberti S, et al. Thrombocytopenia and throm­bocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. Chest. 2010;137(2):416–420.
23. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1994;150(6 Pt 1):1646–1652.
24. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000;356(9240):1480–1485.
25. Hospers JJ, Schouten JP, Weiss ST, Postma DS, Rijcken B. Eosinophilia is associated with increased all-cause mortality after a follow-up of 30 years in a general population sample. Epidemiology. 2000;11(3):261–268.
26. Ulric CS, Frederiksen J. Mortality and markers of risk of asthma death among 1,075 outpatients with asthma. Chest. 1995;108(1):10–15.
27. Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(1):39–47.
28. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(8):867–874.
29. Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomark­ers and exacerbations in chronic obstructive pulmonary disease. JAMA. 2013;309(22):2353–2361.
30. Pinto-Plata VM, Müllerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006;61(1):23–28.
31. Antonescu-Turcu AL, Tomic R. C-reactive protein and copeptin: Prognostic predictors in chronic obstructive pulmonary disease exac­erbations. Curr Opin Pulm Med. 2009;15(2):120–125.
32. Quon BS, Gan WQ, Sin DD. Contemporary management of acute exacerbations of COPD. A systematic review and metaanalysis. Chest. 2008;133(3):756–766.
33. Ford ES. Hospital discharges, readmissions, and ED visits for COPD or bronchiectasis among US adults: findings from the nationwide inpatient sample. 2001–2012 and Nationwide Emergency Department Sample 2006–2011. Chest. 2015;147(4):989–998.
34. Garcia-Aymerich J, Farrero E, Felez MA, et al. Risk factors of readmis­sion to hospital for a COPD exacerbation: a prospective study. Thorax. 2003;58(2):100–105.
35. Jing Z, Chun C, Ning S, et al. Systemic inflammatory marker CRP was better predictor of readmission for AECOPD than sputum inflammatory markers. Arch Bronconeumol. Epub 2015 May 20.
36. Coleta KD, Silveira LV, Lima DF, Rampinelli EA, Godoy I, Godoy I. Predictors of first year survival in patients with advanced COPD treated using long-term oxygen therapy. Respir Med. 2008;102(4):512–518.